Advanced Accelerator (AAAP) Cancer Therapy Approved In EU
Zacks Investment Research | Oct 01, 2017 09:30PM ET
Advanced Accelerator Applications S.A. (NASDAQ:AAAP) announced that the European Commission has authorized the marketing of its drug, Lutathera (lutetium oxodotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NET) in adult patients. The approval allows the company to market the drug in Iceland, Norway and Liechtenstein along with 28 European Union countries.
The drug is under review in the United States. A decision is expected in January 2018.
Shares of the company were up almost 3.9% following the news on Friday. In fact, Advanced Accelerator Applications’ stock is up 152.7% so far this year, significantly outperforming the industry ’s gain of 3.7% in that period.
The approval of the marketing authorization was based on data from a phase III study – NETTER-1 – which showed that Lutathera reduced progression free survival by 79% compared to octreotide LAR in patients with unresectable or metastatic, progressive, somatostatin receptor positive GEP-NET. Although the targeted overall survival (OS) data is yet to be reached, the current data showed 46% reduction in risk of death for Lutathera compared to octreotide.
The marketing authorization application also included efficacy and safety data from a Phase I/II study conducted by Erasmus Medical Center.
Per the European Society for Medical Oncology, GEP-NET occurs in 5.25 persons in a population of 100,000 every year.
The company markets SomaKit TOC in Europe and NETSPOT in the United States in GEP-NET patients for diagnostic purpose. It recorded revenues of €69.2 million in the first six months of 2017, an increase of 27% from the year-ago period.
Lutathera, a peptide receptor radionuclide therapy, is the company’s first drug approved as a therapeutic drug for GEP-NET.
However, Advanced Accelerator Applications recognizes three other radiopharmaceutical products already available in the market. These include Bayer AG’s (OTC:BAYRY) Xofigo for prostate cancer, Zevalin from Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) and GlaxoSmithKline plc’s (NYSE:GSK) Bexxar for non-Hodgkin’s lymphoma.
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.